Final answer:
The nurse should monitor for signs of crystallization in the Osmitrol (mannitol) IV solution before and during administration, as the presence of crystals can cause serious complications.
Step-by-step explanation:
When administering the Osmitrol (mannitol) IV solution, the nurse should foremost monitor for signs of crystallization in the solution. Mannitol can crystallize at room temperature, and introducing such crystals into the bloodstream could lead to serious complications, including embolism. Therefore, it is critical to check the solution for crystallization before and during administration. If crystals are observed, the solution should not be used. Furthermore, to help prevent crystallization, mannitol solutions are often stored in a warmer to maintain a temperature that reduces the risk of crystal formation. While mannitol should not be administered rapidly because of the risk of sudden fluid shifts and electrolyte imbalances, warming the solution is typically not necessary unless it is being kept in a cooler environment that facilitates crystallization. Administering through a peripheral IV line is standard practice unless otherwise indicated, but this would not be the specific action to focus on related to mannitol administration as implied by the question.